iCRT-5

• UNSPSC Description:

  iCRT-5 is a β-catenin-regulated transcription (CRT) inhibitor. iCRT-5 can block Wnt/β-catenin reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma[1][2].

• Target Antigen:

  β-catenin

• Type:

  Reference compound

• Related Pathways:

  Stem Cell/Wnt

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/icrt-5.html

• Purity:

  99.0

• Solubility:

  DMSO : 36 mg/mL (ultrasonic;warming)

• Smiles:

  O=C(O)CCCN(C/1=O)C(SC1=C/C2=CC=C(OC)C(OC)=C2)=S

• Molecular Weight:

  367.44

• References & Citations:

  [1]Käfer R, et, al. Inhibitors of β-catenin affect the immuno-phenotype and functions of dendritic cells in an inhibitor-specific manner. Int Immunopharmacol. 2016 Mar;32:118-124.|[2]Narayanan BA, et, al. Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma. Anticancer Res. 2012 Nov;32(11):4697-707.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  18623-44-4